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1. Introduction
Chronic obstructive pulmonary disease (COPD) is
a common chronic lung disease in clinical and its
characteristic is airflow obstruction. Acute exacerbation
of chronic obstructive pulmonary disease (AECOPD)
refers to a clinical manifestation of sharp deterioration of
cough, expectoration, inhalation or asthmatic in short time
of chronic obstructive pulmonary disease. The sputum
volume increases obviously and the property of sputum
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is mucopurulent that mean the inflammation aggravates 
obviously [1]. Acute exacerbation of COPD can cause 
serious damage to the pulmonary function and may 
develop into pulmonary heart disease, leads to respiratory 
failure and becomes a serious threat to the patients’ safety 
[2]. In recent years, studies have shown that glucocorticoid 
can reduce the clinical symptoms of patients suffering from 
acute exacerbation of COPD and speed up the recovery 
of pulmonary function [3]. In this paper, we observe the 
clinical effect of 55 cases of patients treated with aerosol 
inhalation of budesonide. The report is as follows.
2. Objects and methods
2.1. General information
110 cases of patients with acute exacerbation of chronic
obstructive pulmonary disease, who received treatment
in our hospital from January 2012 to January 2014, were
selected as research objects (69 males, 41 females). The age
was within the range of 50 to 83 years old and the average
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was 69 years old. All patients met the diagnostic criteria 
of COPD established by Respiratory Branch of Chinese 
Medicine Academy [4]. Patients who can’t cooperate 
with treatment, had a history of allergy of glucocorticoid 
and treated with hormone recently were excluded. 110 
cases of patients were divided into control group and 
observation group, 55 cases in each group. According to 
the statistical analysis, the differences in general condition 
and examination indexes of pulmonary function between 
two groups were not statistically significant and the results 
were comparable (p > 0.05).
2.2. Methods of treatment
All patients are routinely treated with anti-infection, 
oxygen inhalation, relieving cough, relieving sputum, 
correcting the balance of water-electrolyte, bronchodilator, 
etc. 2 mL of budesonide suspension (trade name: Pulmicort 
Respules, AstraZeneca in Sweden) was given to observation 
group on the base of routine treatment, the drug was taken 
by aerosol inhalation after imbedding atomizer, one time 
every 15 minutes, twice a day and 5–7 days for a course. 
The control group is treated with methylprednisolone 
intravenous therapy on the basis of routine treatment, 
40–80 mg/day and 5–7 days for a course. In the treatment 
period, we should observe the patients whether they have 
adverse reaction (including clinical adverse reactions and 
laboratory abnormalities) and take appropriate measures in 
time.
2.3. Efficiency standard
Marked effect: within three days after treatment, cough and 
expectoration of patients are obviously relieved, dyspnea, 
ralc and wheezing sounds in lungs disappear, hemogram 
is normal; effective: within three days after treatment, 
cough of patients is obviously relieved, the sputum volume 
is reduced slightly, the dyspnea relieves, the ralc and 
wheezing sounds in lungs reduces and their hemogram 
improves, but not recoveries normally; ineffective; Three 
days after treatment, the symptom and times of cough 
have no improvement or aggravate, the sputum volume is 
unchanged or increased, the dyspnea has no improvement 
or aggravate, the ralc and wheezing sounds in lungs have 
no improvement or aggravate and the hemogram has no 
improvement or increase. The marked effective rate and 
effective rate are calculated as the total efficiency [5].
2.4. Statistics method
Choosing the SPSS 13.0 statistical software to analyze, p < 
0.05, the difference has statistical significance.
3. Results
3.1. Comparison of clinical effect between two groups
The clinical total efficiency of observation group is higher
than the control group. According to the statistical analysis,
the difference of efficacy between control group and
observation group was significant (p < 0.05). The clinical 
effect of observation group is better. See Table 1.
Table 1. Comparison of efficacy between two groups [n (%)].
Group n
Marked 
effect
Effective Ineffective
Total 
efficiency 
（%）
Observation 
group
55 37 （67.3） 13 （23.6） 5 （9.0） 91.0
Control 
group
55 23 （41.8） 20 （36.4） 12 （21.8） 78.2
3.3. Adverse reaction of two groups
Among the patients of observation group who adopted 
aerosol inhalation of budesonide to treat acute exacerbation 
of COPD on the basis of routine treatment, there was one 
case of hoarseness and one case of pharyngodynia. After 
symptomatic treatment, the symptom has disappeared and 
there was no case of increased blood glucose.. As for the 
control group treated with methylprednisolone intravenous 
therapy on the basis of routine treatment, there were two 
cases of oral cavity fungus infection, eight cases of high 
blood glucose and one case of high blood pressure. After 
symptomatic treatment, all the symptoms has disappeared. 
According to the statistical analysis, the difference in the 
occurrence rate of adverse reaction between two groups 
has statistical significance (p < 0.05). The occurrence rate 
of adverse reaction of the observation group is significantly 
lower than the control group.
4. Discussions
COPD is a chronic airway inflammation disease. Related
reports show that the mortality rate of patients who suffer
from acute exacerbation of COPD has reached to 11%
in the hospitalization period [6]. In clinical, the main
methods for treatment of acute exacerbation of COPD
are anti-inflammatory, oxygen inhalation, relieving cough
and so on. In addition, adding glucocorticoid can reduce
the inflammatory response, expand the bronchial and
furthermore improve the efficacy. But the disadvantage
of using glucocorticoid is more adverse reaction and low
security.
   The hormone inhaled therapy has small dosage. The 
drug has a direct effect on target organs without blood 
circulation. Therefore, it has good effect and less side 
effects. Budesonide is a middle efficiency inhaled adrenal 
cortical hormone. Its suspension is used for treatment 
of asthma attack in the past. The aerosol inhalation of 
budesonide can reach the whole lung of patients quickly, 
inhibit the hyperactivity of airway, thus reduce the secretion 
of gland and inhibit the production of mast cells [7]. The 
results of multicenter clinical study show that short-term 
aerosol inhalation of budesonide can significantly improve 
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the clinical symptoms and lung function index of patients 
with acute exacerbation of COPD. Comparing with 
systemic hormone therapy , the efficacy is the same but the 
incidence of side effects decreases [8]. The results of this 
study show that the clinical effect of observation group is 
better than the control group and their incidence of adverse 
reaction is significantly lower than the control group. It 
fully reflects the clinical advantages of aerosol inhalation of 
budesonide in treatment of acute exacerbation of COPD. 
Meanwhile, it also shows the disadvantages of systemic 
hormone therapy. In a word, the aerosol inhalation of 
budesonide in treatment of acute exacerbation of COPD 
has defined effect, less adverse reaction and high security, 
worth of widely application in clinical.
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